Highlights
– A large randomized trial (ESCUDDO; NCT03180034) compared one versus two doses of bivalent and nonavalent HPV vaccines in girls 12–16 years and found one dose was noninferior to two doses for preventing persistent HPV16/18 infection over 5 years.
– Rate differences between one and two doses were small and within the prespecified noninferiority margin (bivalent: -0.13 per 100; nonavalent: 0.21 per 100). Vaccine effectiveness relative to an unvaccinated survey exceeded 97% in each group.
